Product Images Potassium Citrate

This is a description of a medication called Potassium Citrate, which comes in the form of extended-release tablets, USP. Each tablet contains 10mEq (1080 mg) of the medication and there are 500 tablets included in the package, which is only available with a prescription. The tablets are capsule-shaped, uncoated, and off-white to tan-yellowish in color, and are embossed with "T400" on one side and plain on the other. The package insert should be consulted for dosage information. The medication should be stored in a tight container with a child-resistant closure at a temperature range of 20°C to 25°C (68°F to 77°F), with permitted excursions between 15°C to 30°C (59°F to 86°F) as indicated by the USP Controlled Room Temperature guidelines. The medication is manufactured by Ascent Pharmaceuticals, Inc. located in Central Islip, NY.*

This is a description of Potassium Citrate Extended-Release Tablets, USP, which are used for certain medical conditions. The tablets come in a 500-count bottle and each tablet contains 15mEq (1620mg) of potassium citrate. The tablets are oval shaped, off-white or tan-yellowish in color, and uncoated. They are marked with a "T" on one side and "401" on the other. For dosage information, refer to the package insert included with the tablets. The tablets should be stored in a tightly closed container with a child-resistant closure at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The tablets are manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY.*

This is a description of a bottle of Potassium Citrate Extended-Release Tablets, USP containing 500 tablets. Each tablet contains 5 mEq (40mg) and is round and off-white. The bottle should be stored in a tightly closed container with a child-resistant closure between 0°C to 5% and with excursions permitted between 15°C to 30°C. The manufacturer is Ascent Pharmaceuticals located in Central Islip, NY. Refer to the package insert for more information.*

Table 1 shows the effect of Potassium citrate on patients with Calcium Oxalate Nephrolithiasis. The table displays the number of stones formed per year in each group at baseline, on treatment, remission, and any decrease. Additionally, the table provides a definition of remission as "the percentage of patients remaining free of newly formed stones during treatment".*